中國新城鎮(01278.HK):3月底固定收益類項目投資組合總額約為9.3億元
格隆匯 4 月 8日丨中國新城鎮(01278.HK)宣佈,截至2021年3月31日,扣除風險項目的減值準備後,公司固定收益類項目投資組合總額約為人民幣9.3億元。剔除風險項目後,其他項目按照合約取得税前年化保證投資收益約為1億元,對應的平均年化税前投資回報率約為10.3%。
與公司在2020年12月31日所刊發的自願性公吿相比,集團於第一季度內退出江蘇同泰智能製造產業園區項目,並收妥全部的投資本金3,000萬美元和人民幣9,578.6萬元及相關的保證投資收益,退出長春新城項目收回投資本金人民幣1.05億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.